IDEXX Income Tax Expense vs Operating Income Analysis

IDXX Stock

USD 491.29 6.50 1.31%

IDEXX Laboratories financial indicator trend analysis is infinitely more than just investigating IDEXX Laboratories recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether IDEXX Laboratories is a good investment. Please check the relationship between IDEXX Laboratories Income Tax Expense and its Operating Income accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in IDEXX Laboratories. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest.

For more information on how to buy IDEXX Stock please use our How to Invest in IDEXX Laboratories guide.

Income Tax Expense vs Operating Income

Income Tax Expense vs Operating Income Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of IDEXX Laboratories Income Tax Expense account and Operating Income. At this time, the significance of the direction appears to have almost identical trend.

The correlation between IDEXX Laboratories' Income Tax Expense and Operating Income is 0.93. Overlapping area represents the amount of variation of Income Tax Expense that can explain the historical movement of Operating Income in the same time period over historical financial statements of IDEXX Laboratories, assuming nothing else is changed. The correlation between historical values of IDEXX Laboratories' Income Tax Expense and Operating Income is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Income Tax Expense of IDEXX Laboratories are associated (or correlated) with its Operating Income. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Operating Income has no effect on the direction of Income Tax Expense i.e., IDEXX Laboratories' Income Tax Expense and Operating Income go up and down completely randomly.

Correlation Coefficient

0.93

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Income Tax Expense

Operating Income

Operating Income is the amount of profit realized from IDEXX Laboratories operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of IDEXX Laboratories is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.

Most indicators from IDEXX Laboratories' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into IDEXX Laboratories current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in IDEXX Laboratories. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest.

For more information on how to buy IDEXX Stock please use our How to Invest in IDEXX Laboratories guide.At this time, IDEXX Laboratories' Sales General And Administrative To Revenue is fairly stable compared to the past year. Enterprise Value Over EBITDA is likely to rise to 44.60 in 2024, whereas Selling General Administrative is likely to drop slightly above 194 M in 2024.

	2021	2022	2023	2024 (projected)
Gross Profit	1.9B	2.0B	2.2B	2.3B
Total Revenue	3.2B	3.4B	3.7B	3.8B

Gross Profit Total Revenue

IDEXX Laboratories fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Non Current Liabilities Total	Intangible Assets	Short Long Term Debt Total	Short Term Debt	Property Plant And Equipment Gross	Common Stock Total Equity	Common Stock
Total Assets		0.97	0.75	0.73	0.98	0.33	0.91	0.95	0.63	0.98	0.84	0.48	0.99	-0.32	0.97	0.97	-0.92	0.82	0.96	0.77	0.72	0.63	0.11	0.9	0.6	0.54
Other Current Liab	0.97		0.7	0.65	0.99	0.39	0.86	0.97	0.52	0.98	0.88	0.36	0.98	-0.42	0.92	0.95	-0.89	0.85	0.89	0.86	0.7	0.65	0.04	0.88	0.58	0.54
Total Current Liabilities	0.75	0.7		0.19	0.75	0.77	0.52	0.77	0.27	0.69	0.46	0.48	0.72	-0.28	0.76	0.8	-0.65	0.92	0.78	0.73	0.57	0.93	0.73	0.49	0.67	0.67
Total Stockholder Equity	0.73	0.65	0.19		0.64	-0.39	0.89	0.59	0.75	0.72	0.73	0.33	0.71	0.05	0.74	0.65	-0.75	0.2	0.69	0.19	0.61	-0.06	-0.39	0.82	0.25	0.14
Property Plant And Equipment Net	0.98	0.99	0.75	0.64		0.42	0.86	0.96	0.52	0.99	0.85	0.36	0.99	-0.39	0.94	0.96	-0.9	0.86	0.9	0.85	0.69	0.68	0.1	0.86	0.62	0.58
Net Debt	0.33	0.39	0.77	-0.39	0.42		0.0	0.47	-0.29	0.32	0.15	0.1	0.35	-0.52	0.31	0.41	-0.22	0.79	0.31	0.72	0.2	0.91	0.74	0.07	0.47	0.51
Retained Earnings	0.91	0.86	0.52	0.89	0.86	0.0		0.84	0.67	0.92	0.85	0.3	0.9	-0.19	0.93	0.9	-0.97	0.55	0.83	0.5	0.76	0.31	-0.11	0.89	0.41	0.33
Accounts Payable	0.95	0.97	0.77	0.59	0.96	0.47	0.84		0.4	0.97	0.85	0.3	0.97	-0.43	0.93	0.95	-0.89	0.86	0.87	0.83	0.74	0.69	0.15	0.87	0.58	0.53
Cash	0.63	0.52	0.27	0.75	0.52	-0.29	0.67	0.4		0.52	0.39	0.76	0.55	0.18	0.56	0.52	-0.55	0.27	0.73	0.23	0.36	0.11	-0.14	0.61	0.4	0.32
Non Current Assets Total	0.98	0.98	0.69	0.72	0.99	0.32	0.92	0.97	0.52		0.9	0.31	0.99	-0.37	0.96	0.97	-0.94	0.79	0.89	0.78	0.74	0.59	0.03	0.9	0.55	0.5
Non Currrent Assets Other	0.84	0.88	0.46	0.73	0.85	0.15	0.85	0.85	0.39	0.9		0.09	0.88	-0.32	0.83	0.82	-0.83	0.59	0.7	0.62	0.68	0.35	-0.19	0.82	0.38	0.33
Cash And Short Term Investments	0.48	0.36	0.48	0.33	0.36	0.1	0.3	0.3	0.76	0.31	0.09		0.39	0.08	0.39	0.34	-0.23	0.41	0.7	0.31	0.12	0.42	0.3	0.38	0.43	0.39
Net Receivables	0.99	0.98	0.72	0.71	0.99	0.35	0.9	0.97	0.55	0.99	0.88	0.39		-0.38	0.96	0.96	-0.91	0.82	0.92	0.8	0.7	0.62	0.06	0.9	0.57	0.51
Common Stock Shares Outstanding	-0.32	-0.42	-0.28	0.05	-0.39	-0.52	-0.19	-0.43	0.18	-0.37	-0.32	0.08	-0.38		-0.27	-0.32	0.3	-0.5	-0.22	-0.63	0.11	-0.48	-0.02	-0.34	0.13	0.2
Inventory	0.97	0.92	0.76	0.74	0.94	0.31	0.93	0.93	0.56	0.96	0.83	0.39	0.96	-0.27		0.97	-0.93	0.77	0.92	0.68	0.78	0.59	0.17	0.87	0.57	0.5
Other Current Assets	0.97	0.95	0.8	0.65	0.96	0.41	0.9	0.95	0.52	0.97	0.82	0.34	0.96	-0.32	0.97		-0.96	0.83	0.9	0.76	0.8	0.67	0.21	0.83	0.6	0.55
Other Stockholder Equity	-0.92	-0.89	-0.65	-0.75	-0.9	-0.22	-0.97	-0.89	-0.55	-0.94	-0.83	-0.23	-0.91	0.3	-0.93	-0.96		-0.68	-0.82	-0.62	-0.79	-0.48	-0.06	-0.84	-0.49	-0.42
Total Liab	0.82	0.85	0.92	0.2	0.86	0.79	0.55	0.86	0.27	0.79	0.59	0.41	0.82	-0.5	0.77	0.83	-0.68		0.8	0.94	0.51	0.95	0.49	0.6	0.65	0.65
Total Current Assets	0.96	0.89	0.78	0.69	0.9	0.31	0.83	0.87	0.73	0.89	0.7	0.7	0.92	-0.22	0.92	0.9	-0.82	0.8		0.71	0.64	0.66	0.22	0.84	0.62	0.56
Non Current Liabilities Total	0.77	0.86	0.73	0.19	0.85	0.72	0.5	0.83	0.23	0.78	0.62	0.31	0.8	-0.63	0.68	0.76	-0.62	0.94	0.71		0.4	0.85	0.23	0.61	0.55	0.55
Intangible Assets	0.72	0.7	0.57	0.61	0.69	0.2	0.76	0.74	0.36	0.74	0.68	0.12	0.7	0.11	0.78	0.8	-0.79	0.51	0.64	0.4		0.35	0.15	0.64	0.65	0.63
Short Long Term Debt Total	0.63	0.65	0.93	-0.06	0.68	0.91	0.31	0.69	0.11	0.59	0.35	0.42	0.62	-0.48	0.59	0.67	-0.48	0.95	0.66	0.85	0.35		0.69	0.37	0.59	0.62
Short Term Debt	0.11	0.04	0.73	-0.39	0.1	0.74	-0.11	0.15	-0.14	0.03	-0.19	0.3	0.06	-0.02	0.17	0.21	-0.06	0.49	0.22	0.23	0.15	0.69		-0.18	0.43	0.47
Property Plant And Equipment Gross	0.9	0.88	0.49	0.82	0.86	0.07	0.89	0.87	0.61	0.9	0.82	0.38	0.9	-0.34	0.87	0.83	-0.84	0.6	0.84	0.61	0.64	0.37	-0.18		0.38	0.28
Common Stock Total Equity	0.6	0.58	0.67	0.25	0.62	0.47	0.41	0.58	0.4	0.55	0.38	0.43	0.57	0.13	0.57	0.6	-0.49	0.65	0.62	0.55	0.65	0.59	0.43	0.38		0.97
Common Stock	0.54	0.54	0.67	0.14	0.58	0.51	0.33	0.53	0.32	0.5	0.33	0.39	0.51	0.2	0.5	0.55	-0.42	0.65	0.56	0.55	0.63	0.62	0.47	0.28	0.97

Click cells to compare fundamentals

IDEXX Laboratories Account Relationship Matchups

IDEXX Laboratories fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	1.8B	2.3B	2.4B	2.7B	3.3B	3.4B
Other Current Liab	322.9M	415.6M	458.9M	433.7M	478.7M	502.6M
Total Current Liabilities	725.3M	582.8M	763.6M	1.2B	951.5M	999.1M
Total Stockholder Equity	177.5M	632.1M	690.0M	608.7M	1.5B	1.6B
Property Plant And Equipment Net	533.8M	555.2M	587.7M	649.5M	702.2M	737.3M
Net Debt	897.3M	524.6M	779.2M	1.2B	493.9M	255.9M
Retained Earnings	1.6B	2.2B	2.9B	3.6B	4.4B	4.7B
Accounts Payable	72.2M	74.6M	116.1M	110.2M	110.6M	116.2M
Cash	90.3M	383.9M	144.5M	112.5M	453.9M	476.6M
Non Current Assets Total	1.2B	1.2B	1.5B	1.6B	1.8B	1.9B
Non Currrent Assets Other	299.0M	337.2M	397.4M	425.6M	448.5M	470.9M
Cash And Short Term Investments	90.3M	383.9M	144.5M	112.5M	453.9M	476.6M
Net Receivables	269.3M	331.4M	368.3M	400.6M	457.4M	480.3M
Common Stock Shares Outstanding	87.5M	86.7M	86.6M	84.6M	84.0M	94.9M
Liabilities And Stockholders Equity	1.8B	2.3B	2.4B	2.7B	3.3B	3.4B
Inventory	195.0M	209.9M	269.0M	367.8M	380.3M	399.3M
Other Current Assets	125.0M	137.5M	173.8M	220.5M	203.6M	213.8M
Other Stockholder Equity	(1.4B)	(1.5B)	(2.2B)	(2.9B)	(2.9B)	(2.8B)
Total Liab	1.7B	1.7B	1.7B	2.1B	1.8B	1.9B
Total Current Assets	679.6M	1.1B	955.7M	1.1B	1.5B	1.6B
Non Current Liabilities Total	929.3M	1.1B	983.6M	902.2M	823.8M	865.0M
Intangible Assets	58.5M	52.5M	99.0M	97.7M	84.5M	74.5M
Short Long Term Debt Total	987.7M	908.5M	923.7M	1.3B	947.9M	995.3M
Short Term Debt	288.8M	50.0M	148.5M	654.0M	325.0M	208.6M
Property Plant And Equipment Gross	614.5M	646.3M	1.3B	649.5M	1.6B	1.7B
Accumulated Other Comprehensive Income	(46.2M)	(53.6M)	(53.5M)	(77.8M)	(71.2M)	(67.6M)
Common Stock Total Equity	10.6M	10.6M	10.7M	10.7M	12.3M	9.0M
Common Stock	10.6M	10.6M	10.7M	10.7M	10.8M	9.2M
Other Assets	240.2M	676.7M	893.9M	387.5M	445.6M	467.9M
Treasury Stock	(2.3B)	(2.6B)	(2.8B)	(3.6B)	(3.2B)	(3.1B)
Property Plant Equipment	533.8M	555.2M	587.7M	649.5M	746.9M	784.2M
Current Deferred Revenue	41.5M	42.6M	40.0M	37.9M	37.2M	25.0M
Good Will	239.7M	243.3M	359.3M	361.8M	366.0M	206.0M
Other Liab	162.8M	220.5M	208.4M	106.6M	122.6M	83.3M
Long Term Debt	698.9M	858.5M	775.2M	694.4M	622.9M	380.8M
Net Tangible Assets	(120.7M)	336.2M	690.0M	149.3M	134.3M	141.1M
Noncontrolling Interest In Consolidated Entity	264K	280K	352K	707K	813.1K	853.7K
Retained Earnings Total Equity	1.6B	2.2B	2.9B	3.6B	4.1B	4.3B
Long Term Debt Total	698.9M	858.5M	775.2M	694.4M	798.5M	502.0M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether IDEXX Laboratories offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of IDEXX Laboratories' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Idexx Laboratories Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Idexx Laboratories Stock:

How To Invest In IDEXX

Details

Is IDEXX Stock a good investment?

Details

What is IDEXX Laboratories' Net Worth?

Details

Largest Health Care Equipment & Supplies Companies

View

Largest Health Care Equipment & Services Companies

View

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in IDEXX Laboratories. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest.

For more information on how to buy IDEXX Stock please use our How to Invest in IDEXX Laboratories guide.

You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Complementary Tools for IDEXX Stock analysis

When running IDEXX Laboratories' price analysis, check to measure IDEXX Laboratories' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IDEXX Laboratories is operating at the current time. Most of IDEXX Laboratories' value examination focuses on studying past and present price action to predict the probability of IDEXX Laboratories' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IDEXX Laboratories' price. Additionally, you may evaluate how the addition of IDEXX Laboratories to your portfolios can decrease your overall portfolio volatility.

	Fundamental Analysis View fundamental data based on most recent published financial statements
	Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets
	Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios
	AI Investment Finder Use AI to screen and filter profitable investment opportunities
	Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges
	Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market.
	Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios
	Portfolio Anywhere Track or share privately all of your investments from the convenience of any device
	Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk

Is IDEXX Laboratories' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of IDEXX Laboratories. If investors know IDEXX will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about IDEXX Laboratories listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

0.121

Earnings Share

10.07

Revenue Per Share

44.073

Quarterly Revenue Growth

0.088

Return On Assets

0.2283

The market value of IDEXX Laboratories is measured differently than its book value, which is the value of IDEXX that is recorded on the company's balance sheet. Investors also form their own opinion of IDEXX Laboratories' value that differs from its market value or its book value, called intrinsic value, which is IDEXX Laboratories' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because IDEXX Laboratories' market value can be influenced by many factors that don't directly affect IDEXX Laboratories' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between IDEXX Laboratories' value and its price as these two are different measures arrived at by different means. Investors typically determine if IDEXX Laboratories is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, IDEXX Laboratories' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

IDEXX Income Tax Expense vs Operating Income Analysis

Income Tax Expense vs Operating Income

Income Tax Expense vs Operating Income Correlation Analysis

Correlation Coefficient

Income Tax Expense

Operating Income

IDEXX Laboratories fundamental ratios Correlations

IDEXX Laboratories Account Relationship Matchups

High Positive Relationship

High Negative Relationship

IDEXX Laboratories fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for IDEXX Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Net Receivables	+ 0.99	Total Assets
Property Plant And Equipment Net	+ 0.99	Other Current Liab
Non Current Assets Total	+ 0.99	Property Plant And Equipment Net
Net Receivables	+ 0.99	Property Plant And Equipment Net
Net Receivables	+ 0.99	Non Current Assets Total
Property Plant And Equipment Net	+ 0.98	Total Assets

Other Stockholder Equity	- 0.97	Retained Earnings
Other Stockholder Equity	- 0.96	Other Current Assets
Other Stockholder Equity	- 0.94	Non Current Assets Total
Other Stockholder Equity	- 0.93	Inventory
Other Stockholder Equity	- 0.92	Total Assets
Other Stockholder Equity	- 0.91	Net Receivables